Tags

Type your tag names separated by a space and hit enter

Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review.
J Med Virol. 2022 07; 94(7):2969-2976.JM

Abstract

Coronavirus disease 2019 (COVID-19) is an ongoing pandemic, which affected around 45 million confirmed cases of COVID-19, including more than 6 million deaths. However, on November 24, 2021, the World Health Organization announced a new severe acute respiratory syndrome coronavirus 2 variant designated as the B.1.1.529, a variant of concern (VOC), and the variant has been named as "Omicron." Available preliminary evidence suggests that, as compared with previous VOCs, it has an increased risk of infectivity. Studies have shown that protection from various vaccines effectiveness against hospitalization and death from severe COVID-19 disease is decreasing slowly after a two-dose schedule of COVID-19 vaccines. In response to experiencing a new COVID-19 variant and ongoing resurgence of cases, the importance of COVID-19 vaccine booster dose and durability of the effect of the third dose of vaccine against COVID-19 Omicron variant is controversial yet. To address this, we conducted a systematic literature survey on effectiveness of the third or booster dose of COVID-19 vaccine against the Omicron variant. We have performed a systematic search in PubMed (Medline), Google Scholar, and MedRXiv database, from inception to January 2022 using the MeSH terms and keywords "Corona Virus Disease-2019 OR COVID-19 AND Omicron AND COVID-19 Booster Vaccine." We have identified a total of 27 published studies. We have reviewed all the eligible available studies on the effectiveness of the COVID-19 vaccine booster shots against the Omicron variant. This review may be helpful in accelerating the COVID-19 booster dose vaccination.

Authors+Show Affiliations

Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Mangalagiri, Andhra Pradesh, India.Department of Medicine, SVS Medical College and Hospital, Mahabubbnagar, Telangana, India.Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Mangalagiri, Andhra Pradesh, India.Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Mangalagiri, Andhra Pradesh, India.

Pub Type(s)

Journal Article
Review
Systematic Review

Language

eng

PubMed ID

35246846

Citation

Chenchula, Santenna, et al. "Current Evidence On Efficacy of COVID-19 Booster Dose Vaccination Against the Omicron Variant: a Systematic Review." Journal of Medical Virology, vol. 94, no. 7, 2022, pp. 2969-2976.
Chenchula S, Karunakaran P, Sharma S, et al. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. J Med Virol. 2022;94(7):2969-2976.
Chenchula, S., Karunakaran, P., Sharma, S., & Chavan, M. (2022). Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. Journal of Medical Virology, 94(7), 2969-2976. https://doi.org/10.1002/jmv.27697
Chenchula S, et al. Current Evidence On Efficacy of COVID-19 Booster Dose Vaccination Against the Omicron Variant: a Systematic Review. J Med Virol. 2022;94(7):2969-2976. PubMed PMID: 35246846.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. AU - Chenchula,Santenna, AU - Karunakaran,Padmavathi, AU - Sharma,Sushil, AU - Chavan,Madhavrao, Y1 - 2022/03/14/ PY - 2022/01/31/received PY - 2022/03/02/accepted PY - 2022/3/6/pubmed PY - 2022/5/21/medline PY - 2022/3/5/entrez KW - COVID-19 KW - COVID-19 vaccine KW - Omicron KW - SARS CoV-2 KW - booster dose SP - 2969 EP - 2976 JF - Journal of medical virology JO - J Med Virol VL - 94 IS - 7 N2 - Coronavirus disease 2019 (COVID-19) is an ongoing pandemic, which affected around 45 million confirmed cases of COVID-19, including more than 6 million deaths. However, on November 24, 2021, the World Health Organization announced a new severe acute respiratory syndrome coronavirus 2 variant designated as the B.1.1.529, a variant of concern (VOC), and the variant has been named as "Omicron." Available preliminary evidence suggests that, as compared with previous VOCs, it has an increased risk of infectivity. Studies have shown that protection from various vaccines effectiveness against hospitalization and death from severe COVID-19 disease is decreasing slowly after a two-dose schedule of COVID-19 vaccines. In response to experiencing a new COVID-19 variant and ongoing resurgence of cases, the importance of COVID-19 vaccine booster dose and durability of the effect of the third dose of vaccine against COVID-19 Omicron variant is controversial yet. To address this, we conducted a systematic literature survey on effectiveness of the third or booster dose of COVID-19 vaccine against the Omicron variant. We have performed a systematic search in PubMed (Medline), Google Scholar, and MedRXiv database, from inception to January 2022 using the MeSH terms and keywords "Corona Virus Disease-2019 OR COVID-19 AND Omicron AND COVID-19 Booster Vaccine." We have identified a total of 27 published studies. We have reviewed all the eligible available studies on the effectiveness of the COVID-19 vaccine booster shots against the Omicron variant. This review may be helpful in accelerating the COVID-19 booster dose vaccination. SN - 1096-9071 UR - https://www.unboundmedicine.com/medline/citation/35246846/Current_evidence_on_efficacy_of_COVID_19_booster_dose_vaccination_against_the_Omicron_variant:_A_systematic_review_ DB - PRIME DP - Unbound Medicine ER -